Evidence map›Paper›PMID 36757190›Full record

ArticleAntimicrobial agents and chemotherapy2023

Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber

B D VanScoy, S Jones, H Conde, L V Friedrich, N Cotroneo, S M Bhavnani, P G Ambrose

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. The oral penems and carbapenems.Clinical microbiology reviews · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

B D VanScoyInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.ORCID 0000-0001-6527-1475
S JonesInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
H CondeInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
L V FriedrichSpero Therapeutics, Inc., Cambridge, Massachusetts, USA.
N CotroneoSpero Therapeutics, Inc., Cambridge, Massachusetts, USA.ORCID 0000-0002-5267-4176
S M BhavnaniInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.ORCID 0000-0003-4891-6467
P G AmbroseInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.ORCID 0000-0002-2230-1125
Institute for Clinical Pharmacodynamics (United States) · USSpero Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tebipenem is an orally bioavailable carbapenem in development for the treatment of patients with complicated urinary tract infections. Herein, we describe the results of studies designed to evaluate tebipenem's potential as an oral (p.o.) transition therapy from intravenous (i.v.) ertapenem therapy for the most common uropathogen, Escherichia coli. These studies utilized a 7-day hollow-fiber

Indexed as

beta-LactamsEscherichia coliAnti-Bacterial Agentsbeta-LactamasesCarbapenemsErtapenemHumansAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCarbapenemsErtapenemtebipenemertapenemEscherichia coliextended-spectrum β-lactamasehollow-fiber in vitro infection modelin vitrostep-down oral therapytebipenem

Identifiers

PMID36757190
PMCPMC10019163
OpenAlexW4319657237

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read46
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.